Equity Profile

CRMD

CorMedix Inc.

Health CarePharmaceuticals$632.1M

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative products to treat and prevent serious infections in patients with chronic conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.43

Revenue Growth

Revenue growth will indicate how well the company is expanding its market presence and product adoption.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRMD Q2-2026 Earnings Preview

Context

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative products to treat and prevent serious infections in patients with chronic conditions. With a market cap of $1 billion, it operates in the health care sector, which is increasingly important as the demand for effective medical treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+37.26%

Avg Stock Reaction

-1.74%

Last Quarter Recap

In Q1-2026, CorMedix reported an EPS of $0.43, exceeding expectations by 24.64%. The stock rose 5.73% the following day, reflecting positive investor sentiment.

Management Promises & Guidance

Continued focus on product development and market expansion.
Commitment to improving patient outcomes through innovative therapies.
Plans to enhance operational efficiency and cost management.

Expectations

Wall Street Expectations

Overall expectations are mixed as CorMedix has shown strong EPS surprises in the past, but revenue figures remain uncertain. Investors are keen to see if the company can maintain its positive momentum.

Bull Case

If CorMedix delivers another strong EPS surprise and shows signs of revenue growth, it could reinforce investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides weak guidance on revenue, it could lead to a significant drop in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.43

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth will indicate how well the company is expanding its market presence and product adoption.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's strong EPS history, this figure will be crucial in determining market sentiment and stock performance.

What guidance will management provide regarding revenue growth?

Investors will be looking for clarity on future revenue expectations, which are critical for assessing the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CorMedix's ability to exceed EPS expectations due to its recent strong performance and operational improvements.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, suggesting a trend of strong performance.

Options pricing indicates a higher expected move than historical averages, reflecting potential for positive surprises.

Key Risk

If the EPS comes in below $0.40, it could significantly challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CorMedix can sustain its recent performance or if it will face challenges in maintaining growth.

Bull Confirmed If

An EPS of $0.45 or higher would confirm the bullish outlook and suggest continued strong performance.

Bear Confirmed If

An EPS below $0.40 would signal potential issues and confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±22.51%

Historical Avg

±17.1%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty about the upcoming earnings report.

Options are pricing ±22.5% while CRMD has averaged ±17.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (50K)P/C Ratio: 0.11Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CorMedix beats expectations, history suggests the stock could rise by around 2.89% on the first day, confirming a positive outlook.

In-Line / Cautious

If the results are in line with expectations, the stock may experience a muted reaction as investors assess management's commentary.

Miss

Should the company miss expectations, history indicates a potential decline of about 11.52%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future revenue expectations and growth initiatives.
5Responses to analyst questions regarding recent performance trends.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

CorMedix Inc. is a pharmaceutical company focused on developing and commercializing innovative products to treat and prevent serious infections in patients with chronic conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.43

Revenue Growth

Revenue growth will indicate how well the company is expanding its market presence and product adoption.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CRMD Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+37.26%

Avg Stock Reaction

-1.74%

Last Quarter Recap

In Q1-2026, CorMedix reported an EPS of $0.43, exceeding expectations by 24.64%. The stock rose 5.73% the following day, reflecting positive investor sentiment.

Management Promises & Guidance

Continued focus on product development and market expansion.
Commitment to improving patient outcomes through innovative therapies.
Plans to enhance operational efficiency and cost management.

Expectations

Wall Street Expectations

Bull Case

If CorMedix delivers another strong EPS surprise and shows signs of revenue growth, it could reinforce investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides weak guidance on revenue, it could lead to a significant drop in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.43

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth will indicate how well the company is expanding its market presence and product adoption.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's strong EPS history, this figure will be crucial in determining market sentiment and stock performance.

What guidance will management provide regarding revenue growth?

Investors will be looking for clarity on future revenue expectations, which are critical for assessing the company's growth trajectory.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate CorMedix's ability to exceed EPS expectations due to its recent strong performance and operational improvements.

Supporting Evidence

The company has consistently beaten EPS estimates in recent quarters, suggesting a trend of strong performance.

Options pricing indicates a higher expected move than historical averages, reflecting potential for positive surprises.

Key Risk

If the EPS comes in below $0.40, it could significantly challenge the current bullish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether CorMedix can sustain its recent performance or if it will face challenges in maintaining growth.

Bull Confirmed If

An EPS of $0.45 or higher would confirm the bullish outlook and suggest continued strong performance.

Bear Confirmed If

An EPS below $0.40 would signal potential issues and confirm the bearish outlook.

Pre-Earnings Positioning

Options Market

Implied Move

±22.51%

Historical Avg

±17.1%

Pricing rich

The options market is pricing in a significant potential move, indicating uncertainty about the upcoming earnings report.

Options are pricing ±22.5% while CRMD has averaged ±17.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

43.4%

Calls (50K)P/C Ratio: 0.11Puts (2K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CorMedix beats expectations, history suggests the stock could rise by around 2.89% on the first day, confirming a positive outlook.

In-Line / Cautious

If the results are in line with expectations, the stock may experience a muted reaction as investors assess management's commentary.

Miss

Should the company miss expectations, history indicates a potential decline of about 11.52%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Insights into operational efficiencies and cost management strategies.
4Guidance on future revenue expectations and growth initiatives.
5Responses to analyst questions regarding recent performance trends.